DVA Stock Recent News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

Although the stock market has rallied almost non-stop since the start of the year, cracks are beginning to form that indicate a correction may be nearing. Not that I am sounding the alarm for some severe bear market, but rather I would not be surprised to see a garden variety pullback of 5-10% over the next month or so.

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here are the five stocks that qualify our screening criteria ??? RCL, DVA, F, FIS and ITRI.

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The stock market has moved aggressively higher since the start of the year with the S&P 500 gaining 4.6% YTD and the Nasdaq 100 5.2%. While there is nothing inherently wrong with the market showing such strength, there are a few concerning developments brewing that may lead to at least a minor correction in the coming weeks.